McCune-Albright syndrome: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:


==Symptoms==
==Symptoms==
It is suspected when two of the three following features are present:
It is suspected when two of the three following features are present:<ref name="pmid31433921">{{cite journal| author=Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK | display-authors=etal| title=Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. | journal=N Engl J Med | year= 2019 | volume= 381 | issue= 8 | pages= 739-748 | pmid=31433921 | doi=10.1056/NEJMoa1807365 | pmc=6814246 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31433921  }} </ref>
 
* (autonomous) [[endocrine]] hyperfunction such as [[precocious puberty]]
* (autonomous) [[endocrine]] hyperfunction such as [[precocious puberty]]
* [[Fibrous dysplasia]]
* [[Fibrous dysplasia]]

Revision as of 19:09, 2 August 2020

McCune-Albright syndrome
ICD-10 Q78.1
ICD-9 756.54
OMIM 174800
DiseasesDB 7880
MedlinePlus 001217
eMedicine ped/1386 
MeSH D005359

WikiDoc Resources for McCune-Albright syndrome

Articles

Most recent articles on McCune-Albright syndrome

Most cited articles on McCune-Albright syndrome

Review articles on McCune-Albright syndrome

Articles on McCune-Albright syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on McCune-Albright syndrome

Images of McCune-Albright syndrome

Photos of McCune-Albright syndrome

Podcasts & MP3s on McCune-Albright syndrome

Videos on McCune-Albright syndrome

Evidence Based Medicine

Cochrane Collaboration on McCune-Albright syndrome

Bandolier on McCune-Albright syndrome

TRIP on McCune-Albright syndrome

Clinical Trials

Ongoing Trials on McCune-Albright syndrome at Clinical Trials.gov

Trial results on McCune-Albright syndrome

Clinical Trials on McCune-Albright syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on McCune-Albright syndrome

NICE Guidance on McCune-Albright syndrome

NHS PRODIGY Guidance

FDA on McCune-Albright syndrome

CDC on McCune-Albright syndrome

Books

Books on McCune-Albright syndrome

News

McCune-Albright syndrome in the news

Be alerted to news on McCune-Albright syndrome

News trends on McCune-Albright syndrome

Commentary

Blogs on McCune-Albright syndrome

Definitions

Definitions of McCune-Albright syndrome

Patient Resources / Community

Patient resources on McCune-Albright syndrome

Discussion groups on McCune-Albright syndrome

Patient Handouts on McCune-Albright syndrome

Directions to Hospitals Treating McCune-Albright syndrome

Risk calculators and risk factors for McCune-Albright syndrome

Healthcare Provider Resources

Symptoms of McCune-Albright syndrome

Causes & Risk Factors for McCune-Albright syndrome

Diagnostic studies for McCune-Albright syndrome

Treatment of McCune-Albright syndrome

Continuing Medical Education (CME)

CME Programs on McCune-Albright syndrome

International

McCune-Albright syndrome en Espanol

McCune-Albright syndrome en Francais

Business

McCune-Albright syndrome in the Marketplace

Patents on McCune-Albright syndrome

Experimental / Informatics

List of terms related to McCune-Albright syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

McCune-Albright syndrome (polyostotic fibrous dysplasia), described in 1937 by Donovan James McCune and Fuller Albright, is a genetic disorder of bones, skin pigmentation and hormonal problems along with premature puberty.

Symptoms

It is suspected when two of the three following features are present:[1]

Presentation

Within the syndrome there are bone fractures and deformity of the legs, arms and skull, different pigment patches on the skin, and early puberty with increased rate of growth.

Polyostotic fibrous dysplasia has different levels of severity. For example one child may be entirely healthy with no outward evidence of bone or endocrine problems, enter puberty at close to the normal age and have no unusual skin pigmentation. The complete opposite of that would be children who are diagnosed in early infancy with the obvious bone disease and obvious increased endocrine secretions from several glands.

Approximately 20-30% of fibrous dysplasias are polyostotic and two thirds of patients are polyostotic before the age of ten.

Polyostotic fibrous dysplasia is usually caused by mosaicism for a mutation in a gene called GNAS1 (Guanine Nucleotide binding protein, Alpha Stimulating activity polypeptide 1).

The syndrome shows a broad spectrum of severity. The disease frequently involves the skull and facial bones, pelvis, spine and shoulder girdle. The sites of involvement are the femur (91%), tibia (81%), pelvis (78%), ribs, skull and facial bones (50%), upper extremities, lumbar spine, clavicle, and cervical spine, in decreasing order of frequency. The craniofacial pattern of the disease occurs in 50% of patients with the polyostotic form of fibrous dysplasia.

Genetics

Genetically, there is a post-zygotic mutation of the gene GNAS1 which is involved in G-protein signalling. This mutation, often a mosaicism, prevents downregulation of cAMP signalling.

See also

References

  1. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK; et al. (2019). "Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy". N Engl J Med. 381 (8): 739–748. doi:10.1056/NEJMoa1807365. PMC 6814246 Check |pmc= value (help). PMID 31433921.

External links

it:Sindrome di McCune-Albright-Sternberg

Template:WH Template:WikiDoc Sources